Overview

  • Product nameAnti-NFIL3 antibody
    See all NFIL3 primary antibodies
  • Description
    Rabbit polyclonal to NFIL3
  • Tested applicationsSuitable for: WB, IPmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Chimpanzee, Rhesus monkey, Gorilla, Orangutan
  • Immunogen

    Synthetic peptide corresponding to a region within amino acids 412-462 of Human NFIL3 (NP_005375.2).

  • Positive control
    • Whole cell lysate from HeLa cells.

Properties

Associated products

Applications

Our Abpromise guarantee covers the use of ab93785 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/5000. Predicted molecular weight: 51 kDa.
IP Use at 2-5 µg/mg of lysate.

Target

  • FunctionActs as a transcriptional regulator that recognizes and binds to the sequence 5'-[GA]TTA[CT]GTAA[CT]-3', a sequence present in many cellular and viral promoters. Represses transcription from promoters with activating transcription factor (ATF) sites. Represses promoter activity in osteoblasts (By similarity). Represses transcriptional activity of PER1 (By similarity). Represses transcriptional activity of PER2 via the B-site on the promoter (By similarity). Activates transcription from the interleukin-3 promoter in T-cells. Competes for the same consensus-binding site with PAR DNA-binding factors (DBP, HLF and TEF) (By similarity). Component of the circadian clock that acts as a negative regulator for the circadian expression of PER2 oscillation in the cell-autonomous core clock (By similarity). Protects pro-B cells from programmed cell death.
  • Tissue specificityExpressed in bladder stomach, thyroid, spinal cord, lymph node, trachea, adrenal gland, bone marrow and muscle.
  • Sequence similaritiesBelongs to the bZIP family. NFIL3 subfamily.
    Contains 1 bZIP domain.
  • Cellular localizationNucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • E4 promoter binding protein 4 antibody
    • E4 promoter-binding protein 4 antibody
    • E4BP 4 antibody
    • E4BP4 antibody
    • E4BP4 protein antibody
    • IL3BP 1 antibody
    • IL3BP1 antibody
    • Interleukin 3 binding protein 1 antibody
    • Interleukin 3 promoter transcriptional activator antibody
    • Interleukin-3 promoter transcriptional activator antibody
    • Interleukin-3-binding protein 1 antibody
    • NFIL 3 antibody
    • NFIL 3A antibody
    • NFIL3 antibody
    • NFIL3_HUMAN antibody
    • NFIL3A antibody
    • Nuclear factor interleukin 3 regulated antibody
    • Nuclear factor interleukin-3-regulated protein antibody
    • Transcriptional activator NF IL3A antibody
    • Transcriptional activator NF-IL3A antibody
    see all

Anti-NFIL3 antibody images

  • All lanes : Anti-NFIL3 antibody (ab93785) at 0.4 µg/ml

    Lane 1 : Whole cell lysate from HeLa cells at 50 µg
    Lane 2 : Whole cell lysate from HeLa cells at 15 µg
    Lane 3 : Whole cell lysate from HeLa cells at 5 µg

    Developed using the ECL technique

    Predicted band size : 51 kDa


    Exposure time : 3 minutes
  • Detection of NFIL3 in Immunoprecipitates of Whole cell lysate from HeLa cells (1 mg for IP, 20% of IP loaded) using ab93785 at 3 µg/mg lysate for IP (Lane 1) and at 1 µg/ml for subsequent Western blot detection. Lane 2 represents control IgG IP. Detection: Chemiluminescence with an exposure time of 30 seconds.

References for Anti-NFIL3 antibody (ab93785)

This product has been referenced in:
  • Ning H  et al. Conversion of adipose-derived stem cells into natural killer-like cells with anti-tumor activities in nude mice. PLoS One 9:e106246 (2014). WB ; Human . Read more (PubMed: 25162225) »

See 1 Publication for this product

Product Wall

There are currently no Abreviews or Questions for ab93785.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"